This Article Full Text Full Text (PDF) All Versions of this Article: 37/5/1307    most recent 01.STR.0000217398.37075.07v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Omura, T. Articles by Roman, R. J. Search for Related Content PubMed PubMed Citation Articles by Omura, T. Articles by Roman, R. J. Related Collections Acute Cerebral Infarction Neuroprotectors

(Stroke. 2006;37:1307.)
© 2006 American Heart Association, Inc.

Original Contributions

Effect of a New Inhibitor of the Synthesis of 20-HETE on Cerebral Ischemia Reperfusion Injury

Tomohiro Omura, PhD; Yu Tanaka, MS; Noriyuki Miyata, PhD; Chie Koizumi, MS; Takanobu Sakurai, PhD; Misako Fukasawa, MS; Kenji Hachiuma, MS; Toshiya Minagawa, PhD; Teruo Susumu, MS; Shigeru Yoshida, MS; Shiro Nakaike, PhD; Shigeru Okuyama, PhD; David R. Harder, PhD Richard J. Roman, PhD

From the Medicinal Research Laboratories (T.O., Y.T., N.M., C.K., S.Y., S.N.) and the Medicinal Development Research Laboratories (T. Sakurai, M.F., K.H., T.M., S.O.), Taisho Pharmaceutical Co, Ltd, Saitama, Japan; Shin Nippon Biomedical Laboratories Ltd (T. Susumu), Kagoshima, Japan; Cardiovascular Research Center (D.R.H.) and the Department of Physiology (R.J.R.), Medical College of Wisconsin, Milwaukee, Wisc.

Correspondence to Tomohiro Omura, PhD, 1-403 Yoshino-cho, Kita-ku, Saitama-shi, Saitama 331-9530, Japan. E-mail t.omura{at}po.rd.taisho.co.jp

Background and Purpose— Arachidonic acid that is released following cerebral ischemia can be metabolized to 20-hydroxyeicosatetraenoic acid (20-HETE). 20-HETE is a potent vasoconstrictor that may contribute to ischemic injury. This study examined the effects of blockading the synthesis of 20-HETE with TS-011 on infarct size after transient occlusion of the middle cerebral artery (MCAO) of rats and after thromboembolic stroke in monkeys.

Methods— Rats were treated with TS-011 or vehicle at various times after MCAO. Infarct size was measured by 2,3,5-triphenyltetrazolium chloride (TTC) staining and plasma levels of 20-HETE were determined by liquid chromatography mass spectrometry (LC/MS). The effect of TS-011 on infarct size was also studied in monkeys after introduction of a clot into the internal carotid artery.

Results— Plasma levels of 20-HETE increased after MCAO in rats. TS-011 (0.01 to 1.0 mg/kg per hour) reduced infarct volume by 40%. Chronic administration of TS-011 for 7 days reduced neurological deficits after MCAO in rats. TS-011 given in combination with tissue plasminogen activator also improved neurological outcome in the stroke model in monkeys.

Conclusion— These results suggest that blockade of the formation of 20-HETE with TS-011 may be useful for the treatment of ischemic stroke.

Key Words: 20-HETE • brain injury • cytochrome P450 • ischemic stroke

This article has been cited by other articles:

				S. Cao, L.-C. Wang, H. Kwansa, R. J. Roman, D. R. Harder, and R. C. Koehler Endothelin rather than 20-HETE contributes to loss of pial arteriolar dilation during focal cerebral ischemia with and without polymeric hemoglobin transfusion Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2009; 296(5): R1412 - R1418. [Abstract] [Full Text] [PDF]

				K. M. Dunn, M. Renic, A. K. Flasch, D. R. Harder, J. Falck, and R. J. Roman Elevated production of 20-HETE in the cerebral vasculature contributes to severity of ischemic stroke and oxidative stress in spontaneously hypertensive rats Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2455 - H2465. [Abstract] [Full Text] [PDF]

				Y. Mu, M. M. Klamerus, T. M. Miller, L. C. Rohan, S. H. Graham, and S. M. Poloyac Intravenous Formulation of N-Hydroxy-N'-(4-n-butyl-2-methylphenyl)formamidine (HET0016) for Inhibition of Rat Brain 20-Hydroxyeicosatetraenoic Acid Formation Drug Metab. Dispos., November 1, 2008; 36(11): 2324 - 2330. [Abstract] [Full Text] [PDF]

				C. Fava, M. Montagnana, P. Almgren, L. Rosberg, G. Lippi, B. Hedblad, G. Engstrom, G. Berglund, P. Minuz, and O. Melander The V433M Variant of the CYP4F2 Is Associated With Ischemic Stroke in Male Swedes Beyond Its Effect on Blood Pressure Hypertension, August 1, 2008; 52(2): 373 - 380. [Abstract] [Full Text] [PDF]

				V. Nilakantan, C. Maenpaa, G. Jia, R. J. Roman, and F. Park 20-HETE-mediated cytotoxicity and apoptosis in ischemic kidney epithelial cells Am J Physiol Renal Physiol, March 1, 2008; 294(3): F562 - F570. [Abstract] [Full Text] [PDF]

				R. J. Roman and J. H. Lombard Does 20-Hydroxyeicosatetraenoic Acid Contribute to Sex Differences in Cardiovascular Risk by Increasing Oxidative Stress? Hypertension, July 1, 2007; 50(1): 37 - 38. [Full Text] [PDF]